0001636050-21-000033.txt : 20210324
0001636050-21-000033.hdr.sgml : 20210324
20210324192143
ACCESSION NUMBER: 0001636050-21-000033
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210323
FILED AS OF DATE: 20210324
DATE AS OF CHANGE: 20210324
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cheruvu Pavan
CENTRAL INDEX KEY: 0001731741
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 21769594
MAIL ADDRESS:
STREET 1: C/O AXOVANT SCIENCES, INC.
STREET 2: 11 TIMES SQUARE, 33RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sio Gene Therapies Inc.
CENTRAL INDEX KEY: 0001636050
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 853863315
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 130 WEST 42ND STREET
STREET 2: 26TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 877-746-4891
MAIL ADDRESS:
STREET 1: 130 WEST 42ND STREET
STREET 2: 26TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Gene Therapies Ltd.
DATE OF NAME CHANGE: 20190516
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences Ltd.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences, Inc.
DATE OF NAME CHANGE: 20150324
4
1
wf-form4_161662808813010.xml
FORM 4
X0306
4
2021-03-23
0
0001636050
Sio Gene Therapies Inc.
SIOX
0001731741
Cheruvu Pavan
C/O SIO GENE THERAPIES INC.
130 WEST 42ND STREET, 26TH FLOOR
NEW YORK
NY
10036
1
1
0
0
Chief Executive Officer
Common Stock
2021-03-23
4
P
0
100000
2.4818
A
180426
D
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.50 per share, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchase at each separate price within the range set forth in this footnote.
/s/ David Nassif, Attorney-In-Fact
2021-03-24